Accuracy of MRI in prediction of pathologic complete remission in breast cancer after preoperative therapy: a meta-analysis.

OBJECTIVE Prediction of pathologic complete remission in breast cancer after preoperative therapy presents difficulties. We performed a meta-analysis to determine the ability of MRI to predict pathologic complete remission in patients with breast cancer after preoperative therapy. MATERIALS AND METHODS Medical subject heading terms ("MRI" and "Breast Neoplasm") and key words ("neoadjuvant" or "primary systemic" or "preoperative" or "presurgery") were used for a literature search in the MEDLINE database. A meta-analysis of pooled data from eligible studies was performed to estimate the accuracy of MRI in predicting pathologic complete remission after preoperative therapy in patients with breast cancer. RESULTS Twenty-five studies were included in this meta-analysis. Pooled weighted estimates of sensitivity and specificity were 0.63 (range, 0.56-0.70) and 0.91 (range, 90.89-0.92), respectively. Heterogeneity between studies was highly influenced by the pathologic complete remission rate, with a regression coefficient of -6.160 (p = 0.020). Subgroup analysis showed that the specificity of MRI in studies with a pathologic complete remission rate of > or = 20% was lower than that in studies with a pathologic complete remission rate of < 20% (p = 0.0003). CONCLUSION This meta-analysis indicates that MRI has high specificity and relatively lower sensitivity in predicting pathologic complete remission after preoperative therapy in patients with breast cancer. The pathologic complete remission rate may influence the performance of MRI accuracy in this setting, which deserves further investigation.

[1]  Daniele Regge,et al.  Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging , 2004, Breast Cancer Research and Treatment.

[2]  S. Paik,et al.  Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Heywang-Köbrunner.  MRI Evaluation of Pathologically Complete Response and Residual Tumors in Breast Cancer After Neoadjuvant Chemotherapy , 2009 .

[4]  C. Zuiani,et al.  Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy , 2004, European Radiology.

[5]  P J Drew,et al.  Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  J. Ioannidis,et al.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.

[7]  Ying Lu,et al.  Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. , 2002, AJR. American journal of roentgenology.

[8]  A. Cilotti,et al.  Indications for breast magnetic resonance imaging. Consensus document “Attualità in senologia”, Florence 2007 , 2008, La radiologia medica.

[9]  K. Bland,et al.  Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy. , 2011, Clinical breast cancer.

[10]  D. Mankoff,et al.  Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. , 2004, Academic radiology.

[11]  M. Dewhirst,et al.  Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. , 2003, AJR. American journal of roentgenology.

[12]  Per Skaane,et al.  Population-based mammography screening: comparison of screen-film and full-field digital mammography with soft-copy reading--Oslo I study. , 2003, Radiology.

[13]  S. Singletary,et al.  Accuracy of Physical Examination, Ultrasonography, and Mammography in Predicting Residual Pathologic Tumor Size in Patients Treated With Neoadjuvant Chemotherapy , 2006, Annals of surgery.

[14]  I. Ellis,et al.  Early-onset breast cancer--histopathological and prognostic considerations. , 1997, British Journal of Cancer.

[15]  A. Rieber,et al.  Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy , 2002, European Radiology.

[16]  Constance D. Lehman,et al.  Computer-Aided Detection Applied to Breast MRI: Assessment of CAD-Generated Enhancement and Tumor Sizes in Breast Cancers Before and After Neoadjuvant Chemotherapy1 , 2005 .

[17]  D. Hsiang,et al.  Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab. , 2007, Archives of surgery.

[18]  Elkan F Halpern,et al.  Invasive ductal breast carcinoma response to neoadjuvant chemotherapy: noninvasive monitoring with functional MR imaging pilot study. , 2003, Radiology.

[19]  Thomas A Trikalinos,et al.  Meta-analysis methods. , 2008, Advances in genetics.

[20]  S. Loibl,et al.  Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. , 2008, Journal of the National Cancer Institute.

[21]  Janet Waters,et al.  MRI for breast cancer screening, diagnosis, and treatment , 2011, The Lancet.

[22]  Mark A. Helvie,et al.  Clinical and Radiologic Assessments to Predict Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy , 2005, Breast Cancer Research and Treatment.

[23]  C K Kuhl,et al.  Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion MR imaging. , 1997, Radiology.

[24]  J. Stec,et al.  Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  D. Noh,et al.  Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  J R Reichenbach,et al.  Assessment of breast tissue changes on hormonal replacement therapy using MRI: a pilot study. , 1999, Journal of computer assisted tomography.

[27]  Yoshinobu Sato,et al.  Preoperative Evaluation of Residual Tumor Extent by Three‐Dimensional Magnetic Resonance Imaging in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy , 2006, The breast journal.

[28]  P. Bossuyt,et al.  BMC Medical Research Methodology , 2002 .

[29]  L. Brunereau,et al.  Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[30]  Hon J. Yu,et al.  Residual Breast Cancer Diagnosed by MRI in Patients Receiving Neoadjuvant Chemotherapy with and Without Bevacizumab , 2009, Annals of Surgical Oncology.

[31]  D M Shames,et al.  Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. , 1998, AJR. American journal of roentgenology.

[32]  Dianne Georgian-Smith,et al.  Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. , 2005, AJR. American journal of roentgenology.

[33]  W. Kaiser,et al.  High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography: characteristic findings for signal increase and morphological pattern of enhancement. , 2003, The British journal of radiology.

[34]  Ying Lu,et al.  MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer , 2001, Annals of Surgical Oncology.

[35]  Karel G M Moons,et al.  Meta-analysis of MR imaging in the diagnosis of breast lesions. , 2008, Radiology.

[36]  Roman Rouzier,et al.  Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Alan Ashworth,et al.  Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance , 2006, Breast Cancer Research and Treatment.

[38]  Terry L. Smith,et al.  Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Lipsitz,et al.  Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? , 2007, Journal of surgical oncology.

[40]  O. Nalcioglu,et al.  Inflammatory Breast Cancer After Neoadjuvant Chemotherapy: Can Magnetic Resonance Imaging Precisely Diagnose the Final Pathological Response? , 2008, Annals of Surgical Oncology.

[41]  Orhan Nalcioglu,et al.  MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy , 2008, Cancer.

[42]  F. Vicini,et al.  Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy , 2007, Cancer.

[43]  A. Luini,et al.  Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  C. Balu-Maestro,et al.  Imaging in Evaluation of Response to Neoadjuvant Breast Cancer Treatment Benefits of MRI , 2002, Breast Cancer Research and Treatment.

[45]  R. Warren,et al.  Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy? , 2004, British Journal of Cancer.

[46]  Andreas Makris,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  Min-Ying Su,et al.  Monitoring the Size and Response of Locally Advanced Breast Cancers to Neoadjuvant Chemotherapy (Weekly Paclitaxel and Epirubicin) with Serial Enhanced MRI , 2003, Breast Cancer Research and Treatment.

[48]  D. Wickerham,et al.  The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  I. Zuna,et al.  Evaluation of neoadjuvant chemotherapeutic response of breast cancer using dynamic MRI with high temporal resolution , 2002, European Radiology.

[50]  Javier Zamora,et al.  Meta-DiSc : a software for meta-analysis of test accuracy data , 2015 .

[51]  L. Bonomo,et al.  MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. , 2006, Clinical Radiology.

[52]  D. Nitti,et al.  Correlation between Magnetic Resonance Imaging and Histopathological Tumor Response after Neoadjuvant Chemotherapy in Breast Cancer , 2008, Tumori.

[53]  S. Vinnicombe,et al.  Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer , 2008, British Journal of Cancer.

[54]  A. Schneeweiss,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  Baljit Singh,et al.  Breast cancer in young women. , 2008, Journal of the American College of Surgeons.

[56]  H. Junkermann,et al.  Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy , 2003, European Radiology.

[57]  J. Bryant,et al.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.

[58]  D. Tiezzi,et al.  HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination , 2007, BMC Cancer.

[59]  D. Generali,et al.  Magnetic Resonance Imaging in Comparison to Clinical Palpation in Assessing the Response of Breast Cancer to Epirubicin Primary Chemotherapy , 2004, Breast Cancer Research and Treatment.